Tagged with France

France Biogen France is operating at a moment of profound change, where rapid advances in neurology, immunology and rare diseases intersect with shifting global dynamics on investments to innovation and new expectations of industry-public collaboration. In this interview, Marina Vasiliou reflects on how these forces are reshaping the affiliate’s mission, the…

France Dominique Pezziardi oversees International Commercial Operations for Stallergenes Greer, a global biotechnology company specialising in allergy therapeutics. With more than 1,200 employees globally – over 600 based in France – the company maintains a unique positioning as a Swiss-headquartered organisation with deep French industrial roots. Under Pezziardi’s 13-year tenure across…

France Erick Lelouche has served as President of Lyonbiopôle since February 2025, bringing more than 35  years of experience in the pharmaceutical industry across Pfizer and Boehringer Ingelheim, spanning human and animal health in France, Germany, and the US. Together with General Manager Teddy Breyton, whose background lies in regional economic…

France This conversation with Bruno Dubois offers a clear, experience-driven perspective on how Alzheimer’s disease is being redefined, from diagnosis and biomarkers to prevention and early intervention. Drawing on decades at the forefront of neurology, he challenges simplified biological definitions, explains why risk must be stratified with rigour, and outlines a…

France Laurence Peyraut serves as Director General of LEEM (Les Entreprises du Médicament), France’s pharmaceutical industry association representing 270 companies ranging from small French generic manufacturers to major multinational innovators. With two years at LEEM and one year on the EFPIA Board, Peyraut is operating under unprecedented geopolitical pressures reshaping pharmaceutical…

France MaaT Pharma is entering a defining moment in its mission to bring microbiotherapies into areas of acute unmet need. Hervé Affagard recounts how a personal catalyst, an engineering mindset and early scientific partnerships shaped a platform now approaching its first potential approval for its first microbiome drug candidate. The journey…

France Estelle Fruchet, General Manager of Shionogi France since September 2024, brings 25 years of pharmaceutical experience spanning major organisations including Roche, Gilead, and Novartis Gene Therapies. A pharmacist by training with specialisation in product launches – most notably Gilead’s hepatitis C therapy – Estelle Fruchet now leads a 25-person affiliate…

Global 2025 was a year of volatility for pharma and healthcare. In particular, the speed with which the administration of Donald Trump makes (and often then changes) consequential policy decisions has left industry stakeholders in the US and globally scrambling to fall in line. There are already clear winners and losers…

France Genethon sits at the forefront of a fast-accelerating moment in gene medicine, where decades of foundational research are now translating into clinical progress across rare liver, neuromuscular, immune and ophthalmic diseases. In this interview, Frédéric Revah reflects on the organisation’s scientific evolution, its approach to partnerships and access, and the…

France Norgine is redefining what a mid-sized European specialist can achieve, shifting from its gastroenterology heritage into a broader mix of consumer health, women’s health and rare diseases. These changes are taking shape across the organisation, with France playing an important role under Cyril Tavier’s leadership, from implementing new omnichannel models…

France Frederic Collet, Chairman of FIAC (La Filière Intelligence Artificielle et Cancers), leads a pioneering public-private consortium bringing together nine of the world’s most innovative oncology companies with France’s public health institutions. Drawing on extensive oncology expertise and a deep commitment to national competitiveness, he champions a unique model in which…

France Ipsen France is navigating a pivotal moment. The affiliate sits at the intersection of global pipeline expansion, rising expectations for access and renewed national ambition around industrial sovereignty and innovation. In this conversation, Dominique Bery explains how France is shaping Ipsen’s next phase of growth, from oncology leadership to deeper…